Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000 Fax +44 1256 894708
http://www.shire.com
Shire
SHIRE PHARMACEUTICALS GROUP PLC
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: ROBERTS PHARMACEUTICALS OPTION SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 25,471,479
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: 361,283
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 25,110,196
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 134,788,867
AND THE DATE OF ADMISSION: 22 DECEMBER 1999
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: STOCK PURCHASE PLAN
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 59,574
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: NIL
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 59,574
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 1,011,958
AND THE DATE OF ADMISSION: 2 APRIL 1996
(A FURTHER LISTING OF 513,488 SHARES WAS GRANTED ON 19 APRIL 2002)
(A FURTHER LISTING OF 100,000 SHARES WAS GRANTED ON 12 JUNE 2002)
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD
IN ORDER FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: "B" EXECUTIVE SHARE OPTION SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 2,249,283
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: 20,000
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 2,229,283
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 1,750,000
AND THE DATE OF ADMISSION: 12 MARCH 1999
(A FURTHER LISTING OF 3,250,000 SHARES WAS GRANTED IN AUGUST 2001)
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: "A" EXECUTIVE SHARE OPTION SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 183,066
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: 13,761
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 169,305
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 250,000
AND THE DATE OF ADMISSION: 12 MARCH 1999
(A FURTHER LISTING OF 200,000 SHARES WAS GRANTED ON 19 APRIL 2002)
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: SHIRE PHARMACEUTICALS SHARESAVE SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 60,311
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: 11,603
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 48,708
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 247,500
AND THE DATE OF ADMISSION: 21 AUGUST 1999
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: SHIRE RICHWOOD INC SHARE OPTION SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 388,852
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: NIL
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 388,852
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 1,597,816
AND THE DATE OF ADMISSION: 31 MARCH 1999
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: SHIRE LABORATORIES INC SHARE OPTION SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 36,592
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: NIL
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 36,592
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 1,741,654
AND THE DATE OF ADMISSION: 18 MARCH 1998
(A FURTHER LISTING OF 390,226 SHARES WAS GRANTED ON 31 MARCH 1999)
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: SHIRE HOLDINGS LTD SHARE OPTION SCHEME
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 3,040
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: NIL
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 3,040
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 1,011,958
AND THE DATE OF ADMISSION: 31 MARCH 1999
(A FURTHER LISTING OF 318,912 SHARES WAS GRANTED ON 19 APRIL 2002)
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: SHIRE BIOCHEM STOCK OPTION PLAN
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 5,413,561
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: 31,859
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 5,381,702
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 14,822,713
AND THE DATE OF ADMISSION: AUGUST 2001
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
BLOCK LISTING SIX MONTHLY REVIEW
1. NAME OF COMPANY: SHIRE PHARMACEUTICALS GROUP PLC
2. NAME OF SCHEME: TPC WARRANTS
3. PERIOD OF RETURN: FROM: 1 JANUARY 2003 TO: 30 JUNE 2003
4. NUMBER AND CLASS OF SHARES(S)
(AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME
AT END OF THE LAST PERIOD: 1,346,407
5. NUMBER OF SHARES ISSUED/ALLOTTED
UNDER SCHEME DURING PERIOD: NIL
6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED
AT END OF PERIOD: 1,346,407
7. NUMBER AND CLASS OF SHARE(S)
(AMOUNT OF STOCK/DEBT SECURITIES)
ORIGINALLY LISTED: 741,812
AND THE DATE OF ADMISSION: 29 APRIL 2002
(A FURTHER LISTING OF 604,595 SHARES WAS GRANTED ON 27 NOVEMBER 2002)
PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER
FOR US TO UPDATE OUR RECORDS.
477,292,140
For further information please contact:
Mark Prudden - Deputy Company Secretary +44 1256 894 276
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical
company with a strategic focus on meeting the needs of the specialist physician
and currently has a range of projects and products in the areas of central
nervous system (CNS), gastrointestinal (GI), and renal. Shire has operations in
the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and
Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company's website:
www.shire.com